SMAD2 and myelodysplastic syndrome: Immunohistochemical examinations have demonstrated increased levels of phosphorylated or activated SMAD2 (pSMAD2) in bone marrow samples from patients with elevated GDF11 levels, as well as detectable ActRIIB expression in MDS bone marrow samples (Figure 1, E and F).